HK Stock Market Move | KEYMED BIO-B(02162) increased by nearly 3%, its self-developed BCMACD3 bispecific antibody CM336 was granted FTD designation by the FDA.

KEYMED BIO-B (02162) rose nearly 3%, as of the time of writing, it increased by 2.24% to 57 Hong Kong dollars, with a transaction amount of 19.7112 million Hong Kong dollars. On the news front, according to the official WeChat account of KEYMED BIO-B, recently, Connoya and its partner Ouro Medicines Ltd jointly announced that BCMACD3 bispecific CM336 (OM336) has been granted Fast Track Designation (FTD) by the U.S. FDA for the treatment of autoimmune hemolytic anemia (AIHA) and immune thrombocytopenia (ITP). The FTD designation for CM336 in the two indications of AIHA and ITP underscores the urgent need for innovative treatment options for these types of diseases, and once again demonstrates the treatment potential of CM336 in autoimmune diseases. Previously, Connoya entered into an exclusive license agreement with Ouro Medicines Ltd, granting Ouro Medicines the exclusive rights to research, develop, manufacture, register, and commercialize CM336 globally (excluding mainland China, Hong Kong, Macau, and Taiwan). CM336 has already been granted Orphan Drug Designation (ODD) by the FDA for the treatment of AIHA and ITP.